Mr. Smith joined Be Biopharma from Affimed N.V., where he served as Chief Financial Officer from July 2020 to December 2023. During his time at Affimed, Mr. Smith led over $350 million of equity and debt financings for the company. He brings more than 18 years of experience in finance and investment banking within the life sciences and health care industries. His expertise lies in corporate and financial strategy, U.S. capital markets, business development and operations.
Before joining Affimed, Mr. Smith was the Chief Financial Officer at Rockwell Medical, Inc., a biopharmaceutical company specializing in the development and commercialization of anemia therapies. At Rockwell, Mr. Smith elevated his proven track record of financial execution, overseeing the financing of Rockwell’s flagship commercial drug launch and a revamp of the company’s internal controls.
Previously, Mr. Smith held several leadership positions at Pernix Therapeutics, including Senior Vice President, Chief Business Officer and Principal Financial Officer, overseeing Pernix’s financial, M&A and business development strategy. During his tenure at Pernix, Mr. Smith led the execution of several financing transactions and the acquisition of two commercial prescription drugs, aggregating over $500 million in total value.
Mr. Smith began his career in healthcare investment banking, serving most recently as a Director in the Healthcare Investment Banking Group at Cantor Fitzgerald in New York. During his nearly decade-long investment banking career, Mr. Smith specialized in spearheading growth strategies for life sciences and health care companies, resulting in an aggregate transaction value of more than $15 billion. Mr. Smith received a Bachelor of Arts in mathematical economics from Colgate University in Hamilton, New York.